Asunto(s)
Diterpenos , Enfermedades de la Piel , Emulsiones , Femenino , Humanos , Piel , Fenómenos Fisiológicos de la PielRESUMEN
Since 1983 an increasing number of clinical trials have used high-dose melphalan with or without autologous stem cell support in patients with multiple myeloma. It has been shown that high-dose therapy including high-dose melphalan may be considered as the treatment of choice in newly diagnosed patients. The purpose of this report is to review and summarize the clinical information on IV high-dose melphalan in patients with multiple myeloma and to examine potential areas of future investigation.
Asunto(s)
Antineoplásicos Alquilantes/administración & dosificación , Trasplante de Células Madre Hematopoyéticas , Melfalán/administración & dosificación , Mieloma Múltiple/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada , Resistencia a Antineoplásicos , Humanos , Inyecciones Intravenosas , Mieloma Múltiple/tratamiento farmacológico , Acondicionamiento PretrasplanteAsunto(s)
Adenocarcinoma/diagnóstico , Neoplasias Ováricas/diagnóstico , Adenocarcinoma/clasificación , Adenocarcinoma/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada , Femenino , Humanos , Estadificación de Neoplasias , Neoplasias Ováricas/clasificación , Neoplasias Ováricas/terapiaRESUMEN
Chemotherapy-induced emesis is the most severe side effect in term of patient's perception. Current anti-emetic regimen as high dose metoclopramide can achieve a complete response in less than 60% of patients. The HT3 receptors appear to be the principal mediator of the emetic effect and their blockade have a clear activity in the prevention of acute drug-induced emesis, superior to reference regimens.
